Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world.
We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation.
We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have.
As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing.
Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians.
Our Promise
We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation.
We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have.
As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing.
Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians.
Our Promise
We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
Location: France, Ile-de-France, Paris
Employees: 1001-5000
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | CapVest As... | capvest.co... |
| - | CapVest | capvest.co... |
Mentions in press and media 16
| Date | Title | Description |
| 12.01.2026 | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas Mon, Jan 12, 2026 18:00 CET Report this content Clear uptake of uTREAT® in aggressive brain ca... |
| 05.01.2026 | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week Mon, Jan 05, 2026 10:30 CET Report this content Copenhagen, 5 January 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) a clinical-s... |
| 18.12.2025 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer Thu, Dec 18, 2025 17:19 CET Report this content Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uT... |
| 29.10.2025 | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting Wed, Oct 29, 2025 08:10 CET Report this content Part 1 of the trial is completed Part 2 recruitment well underway; completion ... |
| 01.10.2025 | Curasight announces broadening and extension of patent protection for uTRACE® | Curasight announces broadening and extension of patent protection for uTRACE® Wed, Oct 01, 2025 07:00 CET Report this content Issuance of new patent related to uTRACE® will broaden protection Patent coverage has been extended by 751 days an... |
| 02.09.2025 | Curium’s bold vision to treat 80% of cancers within 15 years | LONDON, UNITED KINGDOM, September 2, 2025 /EINPresswire.com/ -- In an exclusive interview with The European’s Juliette Foster, Curium Group CEO Renaud Dehareng outlines his plan to treat up to 80% of cancers within the next few decades, exp... |
| 01.09.2025 | CapVest из Лондона покупает 70% фармпроизводителя Stada у инвестфондов Bain и Cinven за €10 млрд | Лондонская инвестиционная компания приобретает контрольный пакет у нынешних владельцев Stada — фондов частных инвестиций Bain Capital и Cinven, которые сохранят миноритарную долю после завершения сделки, говорится в заявлении в понедельник.... |
| 25.04.2025 | Annual Report for the fiscal year 2024 | Annual Report for the fiscal year 2024 Fri, Apr 25, 2025 08:47 CET Report this content Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year ... |
| 04.04.2025 | Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million | Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million Fri, Apr 04, 2025 17:14 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO TH... |
| 13.01.2025 | Telix Exceeds FY24 Guidance with US$142M Q4 Revenue | MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 D... |
Show more